Yeh YM, Lee CH, Chen SH, et al. - Researchers focused on the clinical usefulness of next-generation sequencing (NGS)-based techniques for determining human epidermal growth factor receptor 2 (HER2) status in colorectal cancer (CRC). Among 73 CRC patients who were managed with surgery and were given adjuvant oxaliplatin treatment and prospectively enrolled in this study, they assessed HER2 changes by means of the Oncomine Comprehensive Assay version 1, as well as clinical outcomes. Ranging from 2.74 to 92.62, HER2 copy number gains were determined in 12 of 73 CRCs, using the NGS-based assay. They identified KRAS and PIK3CA mutations in one and two patients, respectively, among the six HER2-positive CRCs. Overall, the simultaneous detection of HER2 and other genomic changes in patients with CRC could be aided by NGS-based tools. HER2-positivity was seen in only CRCs with HER2 high-level copy number gain, using current diagnostic criteria.